NCT00740116

Tranexamic Acid in Surgery of Advanced Ovarian Cancer

Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Preben Kjolhede, MD, professor · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine if a standardized single dose tranexamic acid given intravenously immediately preoperatively reduces the perioperative bleeding volume and reduces the need of blood transfusion in women undergoing surgery for advanced ovarian cancer.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Tranexamic acid	Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to skin incision at surgery
DRUG	0.9% NaCl solution	0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.

Timeline

• Start date: 2008-03-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2008-08-22
• Last updated: 2022-03-15
• Results posted: 2022-03-15

Locations

3 sites across 1 country: Sweden